These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2143744)

  • 1. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
    Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
    Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
    Martyré MC; Magdelenat H; Bryckaert MC; Laine-Bidron C; Calvo F
    Br J Haematol; 1991 Jan; 77(1):80-6. PubMed ID: 1998600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis.
    Fontenay-Roupie M; Dupuy E; Berrou E; Tobelem G; Bryckaert M
    Blood; 1995 Jun; 85(11):3229-38. PubMed ID: 7756654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease.
    Rueda F; Piñol G; Marti F; Pujol-Moix N
    Acta Haematol; 1991; 85(1):12-5. PubMed ID: 1826402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
    Katoh O; Kimura A; Kuramoto A
    Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease.
    Bernabei PA; Arcangeli A; Casini M; Grossi A; Padovani R; Rossi Ferrini P
    Br J Haematol; 1986 Jun; 63(2):353-7. PubMed ID: 3755056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
    Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
    Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet acquired defect in PDGF and beta thromboglobulin content in hairy cell leukaemia: improvement after interferon therapy.
    Dupuy E; Sigaux F; Bryckaert MC; Tobelem G; Castaigne S; Flandrin G; Degos L; Caen JP
    Br J Haematol; 1987 Jan; 65(1):107-10. PubMed ID: 2949773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
    Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
    Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of PDGF on myeloproliferative disorders].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
    [No Abstract]   [Full Text] [Related]  

  • 11. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
    Kimura A; Katoh O; Kuramoto A
    Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megakaryocytes and platelets in myeloproliferative disorders.
    Briere J; Kiladjian JJ; Peynaud-Debayle E
    Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes.
    Gruber R; Varga F; Fischer MB; Watzek G
    Clin Oral Implants Res; 2002 Oct; 13(5):529-35. PubMed ID: 12453131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 16. [Role of growth factors of platelets (PDGF, TGF-beta, EGF) in the pathogenesis of myelofibrosis].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Byori; 1989 Apr; Spec No 81():1-8. PubMed ID: 2787864
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
    Wehmeier A; Fricke S; Scharf RE; Schneider W
    Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reversible defect of platelet PDGF content in myeloproliferative disorders.
    Baglin TP; Price SM; Boughton BJ
    Br J Haematol; 1988 Aug; 69(4):483-6. PubMed ID: 3408684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.
    Katoh O; Kimura A; Itoh T; Kuramoto A
    Am J Hematol; 1990 Nov; 35(3):145-50. PubMed ID: 2220756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of myelofibrosis in chronic myeloproliferative disorders.
    Yonekura S
    Tokai J Exp Clin Med; 1987 Sep; 12(3):141-5. PubMed ID: 3331217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.